

[OPP-31083A; PH-FRL 2527-5]

Kimberly Clark Corp.; Approval of Application to Conditionally Register a Pesticide Product Involving a Changed Use Pattern**AGENCY:** Environmental Protection Agency (EPA).**ACTION:** Notice.

SUMMARY: EPA has approved the application by Kimberly Clark Corp. to conditionally register the product Kleenex Avert Virucidal Tissue, involving a changed use pattern pursuant to the provisions of section 3(c)(4) of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended.

FOR FURTHER INFORMATION CONTACT:

By mail: Arturo Castillo, Product Manager PM 32, Registration Division (TS-767C), Office of Pesticide Programs, Environmental Protection Agency, 401 M St., SW., Washington, D.C. 20460.

Office location and telephone number: Rm. 244, CM#2, 1921 Jefferson Davis Highway, Arlington, VA 22202, (703-557-3965).

SUPPLEMENTARY INFORMATION: EPA issued a notice published in the *Federal Register* of August 31, 1983 (48 FR 39501), which announced that Kimberly Clark Corp., PO Box 999, Neenah, WI 54956, had submitted an application to conditionally register the product Kleenex Virucidal Tissue containing the active ingredients citric acid at 10 percent, malic acid at 5 percent, and sodium lauryl sulfate at 2 percent. The application proposed a changed use pattern of the product.

The application was approved on December 16, 1983 for general use as a chemically impregnated dry facial tissue. The product was assigned EPA Registration No. 9402-3.

A copy of the approved label and the list of data references used to support registration are available for public inspection in the office of the product manager. The data and other scientific information used to support registration will be available for public inspection in accordance with section 3(c)(2) of FIFRA within 30 days after registration date. Requests for data must be made in accordance with the provisions of the Freedom of Information Act and must be addressed to the Freedom of Information Office (A-101), EPA, 401 M St., SW., Washington, D.C. 20460. Such requests should: (1) identify the product name and registration number and (2) specify the data or information desired. (Sec. 3(c)(2) FIFRA, as amended)

Dated: February 4, 1984.

Edwin L. Johnson,

Director, Office of Pesticide Programs.

[FR Doc. 84-4028 Filed 2-14-84; 8:45 am]

BILLING CODE 6560-50-M

[OW-FRL 2522-2]

Water Quality Criteria; Availability of Document**AGENCY:** Environmental Protection Agency.**ACTION:** Notice of Final Ambient Water Quality Criteria Document.

SUMMARY: EPA announces the availability and provides a summary of a final ambient water quality criteria document for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). These criteria are published pursuant to section 304(a)(1) of the Clean Water Act.

Availability of Document

A summary of the criteria from this document is published below. Copies of the complete document may be obtained from the person listed below. This document is also available for public inspection and copying during normal business hours at the Public Information Reference Unit, U.S. Environmental Protection Agency, Room 2404 (rear), 401 M St., S.W., Washington, D.C. 20460. As provided in 40 CFR Part 2, a reasonable fee may be charged for copying services. Copies of this document are also available for review in the EPA Regional Office libraries.

FOR FURTHER INFORMATION CONTACT: Dr. Frank Gostomski, Criteria and Standards Division (WH-585), United States Environmental Protection Agency, 401 M Street, S.W., Washington, D.C. 20460, (202) 245-3030.

SUPPLEMENTARY INFORMATION:**Background**

Pursuant to section 304(a)(1) of the Clean Water Act, 33 U.S.C. 1314(a)(1), EPA is required to periodically review and publish criteria for water quality accurately reflecting the latest scientific knowledge:

(A) on the kind and extent of all identifiable effects on health and welfare including, but not limited to, plankton, fish, shellfish, wildlife, plant life, shorelines, beaches, esthetics, and recreation which may be expected from the presence of pollutants in any body of water, including groundwater, (B) on the concentration and dispersal of pollutants, or their byproducts, through biological, physical, and chemical processes, and (C) on the effects of pollutants on biological community diversity, productivity, and stability, including information on the factors affecting rates of eutrophication and

rates of organic and inorganic sedimentation for varying types of receiving waters.

On November 28, 1980, EPA announced the availability of final ambient water quality criteria documents for 64 of the 65 pollutants designated as toxic under section 307(a)(1) of the Clean Water Act (45 FR 79318). An initial draft criteria document for the remaining pollutant, TCDD, was made available for public comment on March 15, 1979 (44 FR 15926). After consideration of all comments received from the public and peer reviewers, final criteria for TCDD have been derived.

A complete description of the water quality criteria program, including the use of criteria in water quality standards, the methodologies used to derive criteria, and the response to public comment were published in the *Federal Register* on November 28, 1980 (45 FR 79318).

Summary of Criteria:**2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN***Aquatic Life*

Not enough data are available concerning the effects of 2,3,7,8-TCDD on aquatic life and its uses to allow derivation of national criteria. The available information indicates that acute values for some freshwater animal species are above 1.0 µg/l; some chronic values are below 0.01 µg/l, and the chronic value for rainbow trout is below 0.001 µg/l. Because exposures of some species of fishes to 0.01 µg/l for less than six days resulted in substantial mortality several weeks later, derivation of aquatic life criteria for 2,3,7,8-TCDD may require special consideration. Estimated bioconcentration factors (BCFs) for 2,3,7,8-TCDD range from 3,000 to 900,000, but the available measured BCFs range from 390 to 13,000. If the BCF is 5,000, concentrations above 0.00001 µg/l should result in concentrations in edible freshwater and saltwater fish and shellfish that exceed levels identified in an FDA health advisory. If the BCF is greater than 5,000 or if uptake in a field situation is greater than that in laboratory tests, concentrations of less than 0.00001 µg/l could result in exceedence of levels in the FDA health advisory.

Human Health

For the maximum protection of human health from the potential carcinogenic effects due to exposure to 2,3,7,8-TCDD through ingestion of contaminated water and contaminated aquatic organisms, the ambient water concentration should be zero based on the non-threshold

assumption for this chemical. However, zero level may not be attainable at the present time. Therefore, the levels that may result in an increase of cancer risk over the lifetime are estimated at 10^{-5} , 10^{-6} , and 10^{-7} . The corresponding recommended criteria are 1.3×10^{-7} $\mu\text{g/l}$, 1.3×10^{-8} $\mu\text{g/l}$, and 1.3×10^{-9} $\mu\text{g/l}$, respectively. If the above estimates are made for consumption of aquatic organisms only, excluding consumption of water, the levels are 1.4×10^{-7} $\mu\text{g/l}$, 1.4×10^{-8} $\mu\text{g/l}$, and 1.4×10^{-9} $\mu\text{g/l}$, respectively. Other concentrations representing different risk levels may be calculated. The risk estimate range is presented for information purposes and does not represent an Agency judgment on an "acceptable" risk level.

Dated: February 2, 1984.

Jack E. Ravan,

Assistant Administrator for Office of Water.

[FR Doc. 84-3382 Filed 2-14-84; 8:45 am]

BILLING CODE 6560-50-M

FEDERAL RESERVE SYSTEM

Bankers Trust New York Corp., et al.; Applications to engage de novo in Permissible Nonbanking Activities

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (40 FR 794) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (49 FR 794) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing,

identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 5, 1984.

A. Federal Reserve Bank of New York (A. Marshall Puckett, Vice President) 33 Liberty Street, New York, New York 10045:

1. *Bankers Trust New York Corporation*, New York, New York, to engage *de novo* through its subsidiary, BT Futures Corp., in executing and clearing options on futures contracts in foreign exchange on the international monetary market division of the Chicago Mercantile Exchange and its affiliated clearing association.

B. Federal Reserve Bank of Kansas City (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Talmage Investment, Inc.*, Talmage, Kansas, to engage *de novo* through its subsidiary, Talmage Insurance Agency, Talmage, Kansas, in the sale of general insurance in a town with a population not exceeding 5,000. These activities would be performed in the Village of Talmage, Kansas and the surrounding rural area.

C. Federal Reserve Bank of San Francisco (Harry W. Green, Vice President) 101 Market Street, San Francisco, California 94105:

1. *BankAmerica Corporation*, San Francisco, California; to engage worldwide through a *de novo* office of its subsidiary, BA Investment Management Corporation, in London, England, in acting as investment and financial advisor including, but not limited to, acting as investment advisor as defined in the Investment Company Act of 1940, providing portfolio investment advice and furnishing general economic information and advice, general economic statistical forecasting services and industry studies, pursuant to § 225.25(b)(4) of Regulation Y.

Board of Governors of the Federal Reserve System, February 9, 1984.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 84-3984 Filed 2-14-84; 8:45 am]

BILLING CODE 6210-01-M

BSB Financial Corp.; et al. Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (49 FR 794) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than March 9, 1984.

A. Federal Reserve Bank of Philadelphia (Thomas K. Desch, Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *BSB Financial Corporation*, Trenton, New Jersey; to become a bank holding company by acquiring 100 percent of the voting shares of The Broad Street National Bank of Trenton, Trenton, New Jersey.

B. Federal Reserve Bank of Cleveland (Lee S. Adams, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44115:

1. *Farmers State Bancorp, Inc.*, Booneville, Kentucky; to become a bank holding company by acquiring 100 percent of the voting shares of Farmers State Bank, Booneville, Kentucky.

C. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, NW., Atlanta, Georgia 30303:

1. *First National Bancorp of the South, Inc.*, Opp, Alabama; to acquiring 100 percent of the voting shares of First National Bank of Andalusia, Andalusia, Alabama.